Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.65 CHF | -1.47% | +1.87% | +23.65% |
Sales 2024 * | 182M 200M | Sales 2025 * | 206M 226M | Capitalization | 535M 589M |
---|---|---|---|---|---|
Net income 2024 * | 23M 25.32M | Net income 2025 * | 35M 38.53M | EV / Sales 2024 * | 3.26 x |
Net Debt 2024 * | 57.88M 63.72M | Net Debt 2025 * | 12.51M 13.77M | EV / Sales 2025 * | 2.66 x |
P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
18.7
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
1 day | -1.30% | ||
1 week | +1.98% | ||
Current month | +10.89% | ||
1 month | +5.04% | ||
3 months | +17.27% | ||
6 months | +21.84% | ||
Current year | +24.08% |
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 14-08-31 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 08-12-31 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 17-04-26 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-12-31 |
Director/Board Member | 69 | 13-04-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 746 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 34 M€ | +4.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 43.65 | -1.47% | 13 626 |
24-05-16 | 44.3 | +0.91% | 46,457 |
24-05-15 | 43.9 | -1.35% | 35,330 |
24-05-14 | 44.5 | +3.25% | 40,475 |
24-05-13 | 43.1 | +0.35% | 23,536 |
Delayed Quote Swiss Exchange, May 17, 2024 at 10:26 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.08% | 591M | |
+32.09% | 50.85B | |
+0.84% | 42.82B | |
+48.94% | 42.03B | |
-4.22% | 29.55B | |
+10.95% | 26.11B | |
-21.72% | 19.13B | |
+8.31% | 13.05B | |
+26.74% | 12.16B | |
+23.39% | 12.08B |
- Stock Market
- Equities
- BSLN Stock